Friday, 31 Oct 2025
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
logo logo
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
  • 🔥
  • Trump
  • VIDEO
  • House
  • White
  • ScienceAlert
  • Trumps
  • Watch
  • man
  • Health
  • Season
Font ResizerAa
American FocusAmerican Focus
Search
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
Follow US
© 2024 americanfocus.online – All Rights Reserved.
American Focus > Blog > Health and Wellness > A New Approach To Childhood Neuroblastoma
Health and Wellness

A New Approach To Childhood Neuroblastoma

Last updated: February 27, 2025 7:27 am
Share
A New Approach To Childhood Neuroblastoma
SHARE

Childhood neuroblastoma is a devastating disease that often leads to fatal outcomes. Despite the initial success of treatment, many patients experience relapse or develop resistance to existing therapies. However, a new approach utilizing a combination of two drugs has shown promise in reducing relapse rates and improving long-term survival for children with neuroblastoma.

The current standard treatment for neuroblastoma involves the use of topoisomerase inhibitors, which work by disrupting DNA replication. While these drugs can induce remission, the overall long-term survival rate remains unfavorable. In an effort to improve outcomes, a new strategy has been developed that combines traditional topoisomerase inhibitor-based therapy with a monoclonal antibody known as bevacizumab (B).

Bevacizumab inhibits blood vessel formation, a process that tumors rely on to grow and spread. By blocking key growth factors required for blood vessel formation, this antibody has the potential to enhance the effectiveness of existing treatments. In a recent study, children with neuroblastoma were enrolled in a trial known as BEACON, which evaluated the efficacy of combining topoisomerase inhibitors with bevacizumab.

The BEACON trial utilized an innovative design that allowed for the evaluation of multiple treatment combinations. Children were divided into four groups, each receiving different combinations of topoisomerase inhibitors with or without bevacizumab. The results showed that the combination therapy of bevacizumab, irinotecan, and temozolomide had a significantly higher response rate and improved long-term survival compared to standard therapy alone.

One unexpected benefit of the combination therapy was the interaction between irinotecan and bevacizumab, which showed a significant impact on tumor response. The antibody may stimulate the presence of tumor-fighting lymphocytes, enhancing the overall effectiveness of the treatment. By cutting off the blood supply to the tumor and disrupting its ability to repair DNA damage, the combination therapy creates a hostile environment for neuroblastoma cells, making them more vulnerable to treatment.

See also  Merck's RSV treatment for infants is approved by FDA

While the results of the BEACON trial are promising, there is still room for improvement. Further research is needed to explore the potential benefits of incorporating additional drugs or antibodies into the treatment regimen. By continuing to investigate new combination therapies, we may be able to further improve response rates and long-term survival for children with neuroblastoma.

Overall, the BEACON trial offers hope for children and families affected by neuroblastoma. This groundbreaking research has the potential to pave the way for future advancements in the treatment of this aggressive disease, ultimately leading to improved outcomes and increased survival rates.

TAGGED:approachChildhoodNeuroblastoma
Share This Article
Twitter Email Copy Link Print
Previous Article TimothĂ©e Chalamet ‘Sparks Slimming Craze After 20lbs Weight Gain For Dylan Role’ TimothĂ©e Chalamet ‘Sparks Slimming Craze After 20lbs Weight Gain For Dylan Role’
Next Article Bryan Kohberger’s lawyers may cite autism to try to strike death penalty option: court documents Bryan Kohberger’s lawyers may cite autism to try to strike death penalty option: court documents
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Popular Posts

The dangers of so-called AI experts believing their own hype

Demis Hassabis, CEO of Google DeepMind and a Nobel prizewinner for his role in developing…

July 5, 2025

Identity is the Breaking Point—Get It Right or Zero Trust Fails

The Rise of Deepfakes and Identity-Based Cyber Threats This article is part of VentureBeat’s special…

March 10, 2025

What Can California Learn From Other States About State Transmission Authorities?

State transmission authorities play a crucial role in helping states develop transmission infrastructure, particularly when…

June 10, 2025

Suspended PGA Tour pro expresses disappointment “in the TOUR” over Grant Horvat’s Barracuda Championship situation

Grant Horvat has made a bold decision by declining an invitation to participate in the…

July 16, 2025

BeyoncĂ© Brings Out Destiny’s Child For Finale Cowboy Carter Tour

Bayern Munich has been on a roll in the transfer market this summer, already securing…

July 28, 2025

You Might Also Like

As Medicaid work requirements loom, study finds links between coverage, better health and higher employment
Health and Wellness

As Medicaid work requirements loom, study finds links between coverage, better health and higher employment

October 31, 2025
Digital Twins Coming To Robotic Surgery
Health and Wellness

Digital Twins Coming To Robotic Surgery

October 31, 2025
Medicare, midterm elections, Vinay Prasad: Morning Rounds
Health and Wellness

Medicare, midterm elections, Vinay Prasad: Morning Rounds

October 31, 2025
Remission achievable for 1 in 3 Indian diabetics through intensive app-based lifestyle program, study suggests
Health and Wellness

Remission achievable for 1 in 3 Indian diabetics through intensive app-based lifestyle program, study suggests

October 31, 2025
logo logo
Facebook Twitter Youtube

About US


Explore global affairs, political insights, and linguistic origins. Stay informed with our comprehensive coverage of world news, politics, and Lifestyle.

Top Categories
  • Crime
  • Environment
  • Sports
  • Tech and Science
Usefull Links
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA

© 2024 americanfocus.online –  All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?